Crinetics Pharmaceuticals... (CRNX)
| Bid | 32.55 |
| Market Cap | 3.23B |
| Revenue (ttm) | 1.06M |
| Net Income (ttm) | -303.48M |
| EPS (ttm) | -3.69 |
| PE Ratio (ttm) | -9.42 |
| Forward PE | -9.83 |
| Analyst | Buy |
| Ask | 36.79 |
| Volume | 482,465 |
| Avg. Volume (20D) | 995,405 |
| Open | 34.84 |
| Previous Close | 34.90 |
| Day's Range | 34.10 - 35.25 |
| 52-Week Range | 31.84 - 62.53 |
| Beta | 0.58 |
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat c...
Analyst Forecast
According to 13 analyst ratings, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is $73.5, which is an increase of 111.45% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call TranscriptCrinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q4 2024 Results Conference Call February 27, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and...
2 months ago · seekingalpha.com
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market WeaknessCrinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, ...